Last reviewed · How we verify

Healive+Havrix — Competitive Intelligence Brief

Healive+Havrix (Healive+Havrix) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated viral vaccine combination. Area: Immunology / Infectious Disease.

marketed Inactivated viral vaccine combination Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

Healive+Havrix (Healive+Havrix) — Sinovac Biotech Co., Ltd. Healive+Havrix is a combination vaccine that provides immunization against hepatitis A and hepatitis B through inactivated viral antigens.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Healive+Havrix TARGET Healive+Havrix Sinovac Biotech Co., Ltd marketed Inactivated viral vaccine combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated viral vaccine combination class)

  1. Sinovac Biotech Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Healive+Havrix — Competitive Intelligence Brief. https://druglandscape.com/ci/healive-havrix. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: